文献速递腹部CT

不同辐射剂量与重建方法对肝转移瘤检出的观察者效能

Observer Performance with Varying Radiation Dose and Reconstruction Methods for Detection of Hepatic Metastases.
PubMed 文献 · Radiology · 2018-09-11

研究基于83例增强CT投影数据,比较80至200质量参考mAs五个剂量水平下FBP与迭代重建对肝转移瘤的检出能力。结果显示120质量参考mAs(体型特异性剂量估计8.0 mGy)及以上剂量与200质量参考mAs FBP效能相当,100质量参考mAs FBP未达非劣效标准,迭代重建改善图像质量但未提升阅片者效能。

要点

  • 120质量参考mAs(体型特异性剂量估计8.0 mGy)及以上剂量与200质量参考mAs FBP检出肝转移瘤效能相当。
  • 100质量参考mAs FBP未达非劣效标准,与常规剂量的效能差异为-0.08(95%CI:-0.11,-0.04)。
  • 迭代重建改善图像质量(P < .05),但未提升阅片者检出效能。

核心结论

  • 对于增强CT检出肝转移瘤,120质量参考mAs(体型特异性剂量估计8.0 mGy)及以上剂量与200质量参考mAs FBP效能相似。

研究设计与样本

  • 基于83例增强CT检查投影数据的观察者效能研究,由3名腹部放射科医师阅片,转移瘤以组织病理学分析或进展与消退定义。

关键影像表现/征象

  • 共123个肝转移瘤,平均大小1.4 cm。
  • 中位容积CT剂量指数为11.0 mGy,中位体型特异性剂量估计为13.4 mGy。

诊断标准与关键数值

  • 采用JAFROC分析评估非劣效性,非劣效界值为-0.10。
  • 100质量参考mAs FBP未达非劣效标准,与常规剂量的估计效能差异为-0.08(95%CI:-0.11,-0.04)。
  • 预设阅片者一致性规则在100质量参考mAs迭代重建或80质量参考mAs迭代重建未达标,在120质量参考mAs及以上剂量(即体型特异性剂量估计≥8.0 mGy)达标。
  • 除160质量参考mAs迭代重建外,较低剂量水平与转移瘤检出信心降低相关(P < .001)。
  • 迭代重建改善图像质量(P < .05),但未改善阅片者效能。

临床应用与阅片要点

  • 作者结论认为,120质量参考mAs(体型特异性剂量估计8.0 mGy)及以上剂量与200质量参考mAs FBP检出肝转移瘤效能相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To estimate the ability of lower dose levels and iterative reconstruction (IR) to display hepatic metastases that can be detected by radiologists. Materials and Methods Projection data from 83 contrast agent-enhanced CT examinations were collected. Metastases were defined by histopathologic analysis or progression and regression. Lower radiation dose configurations were reconstructed at five dose levels with filtered back projection (FBP) and IR (automatic exposure control settings: 80, 100, 120, 160, and 200 quality reference mAs [QRM]). Three abdominal radiologists circumscribed metastases, indicating confidence (confidence range, 0-100) and image quality. Noninferiority was assessed by using jackknife alternative free-response receiver operating characteristic (JAFROC) analysis (noninferiority limit, -0.10) and reader agreement rules, which required identification of metastases identified at routine dose, and no nonlesion localizations in patients negative for metastases, in 71 or more patient CT examinations (of 83), for each configuration. Results There were 123 hepatic metastases (mean size, 1.4 cm; median volume CT dose index and size-specific dose estimate, 11.0 and 13.4 mGy, respectively). By using JAFROC figure of merit, 100 QRM FBP did not meet noninferiority criteria and had estimated performance difference from routine dose of -0.08 (95% confidence interval: -0.11, -0.04). Preset reader agreement rules were not met for 100 QRM IR or 80 QRM IR, but were met for doses 120 QRM or higher (ie, size-specific dose estimate ≥ 8.0 mGy). IR improved image quality (P < .05) but not reader performance. Other than 160 QRM IR, lower dose levels were associated with reduced confidence in metastasis detection (P < .001). Conclusion For detection of hepatic metastases by using contrast-enhanced CT, dose levels that corresponded to 120 quality reference mAs (size-specific dose estimate, 8.0 mGy) and higher performed similarly to 200 quality reference mAs with filtered back projection. © RSNA, 2018 Online supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Fletcher JG, Fidler JL, Venkatesh SK, et al. Observer Performance with Varying Radiation Dose and Reconstruction Methods for Detection of Hepatic Metastases. Radiology. 2018. PMID: 30204077. doi:10.1148/radiol.2018180125

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。